All In Biotech

Drug Trial Radar · NCT05349214

Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

A Randomized, Double-blind, Placebo Controlled, 3-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (NEPTUNUS-2)

Last checked: Nov 20, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 506 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

506

Actual

Start

Aug 4, 2022

Primary completion

May 13, 2025

Study completion Apr 15, 2027

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Apr 27, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A randomized, double-blind, placebo controlled, 3-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjogren's syndrome (NEPTUNUS-2)

Conditions

  • Sjogren Syndrome

Interventions

  • VAY736Biological

    ianalumab s.c.

  • PlaceboOther

    placebo s.c.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Plan A and B - Change from baseline in ESSDAI score at Week 48Time frame: 48 weeks

Locations

146 sites in 26 countries. Site status is shown where the registry gives one.

  • Providence Medical Foundation

    Fullerton, California

  • Advanced Medical Research

    La Palma, California

  • Bay Area Arthritis And Osteoporosis

    Brandon, Florida

  • GNP Research

    Cooper City, Florida

  • Sarasota Arthritis Res Ctr

    Sarasota, Florida

  • Augusta University Georgia

    Augusta, Georgia

  • North Georgia Rheumatology Group

    Lawrenceville, Georgia

  • Clin Invest Specialists Inc

    Orland Park, Illinois

  • Clinic of Robert Hozman

    Skokie, Illinois

  • Clinical Investigation Specialists, Inc.

    Wauconda, Illinois

  • University of Kansas Hospital

    Kansas City, Kansas

  • Tufts School of Dental Medicine

    Boston, Massachusetts

  • Arthritis Osteoporosis Assoc of NM

    Las Cruces, New Mexico

  • St Lawrence Health System

    Potsdam, New York

  • Arthritis and Osteoporosis

    Charlotte, North Carolina

  • On Site Clinical Solutions Llc

    Charlotte, North Carolina

  • RAO Research LLC

    Oklahoma City, Oklahoma

  • West Tennessee Research Institute

    Jackson, Tennessee

  • Ramesh C Gupta MD Memphis TN

    Memphis, Tennessee

  • Prolato Clinical Research Center

    Houston, Texas

  • First Outpatient Research Unit

    San Antonio, Texas

  • Advanced Rheumatology of Houston

    Spring, Texas

  • Arthritis Northwest PLLC

    Spokane, Washington

  • Novartis Investigative Site

    Buenos Aires, Argentina

  • Novartis Investigative Site

    Buenos Aires, Argentina

  • Novartis Investigative Site

    Buenos Aires, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    Quilmes, Buenos Aires, Argentina

  • Novartis Investigative Site

    San Miguel Tucuman, Tucumán Province, Argentina

  • Novartis Investigative Site

    Maroochydore, Queensland, Australia

  • Novartis Investigative Site

    Woodville South, South Australia, Australia

  • Novartis Investigative Site

    Hobart, Tasmania, Australia

  • Novartis Investigative Site

    Salvador, Estado de Bahia, Brazil

  • Novartis Investigative Site

    Curitiba, Paraná, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    Burgas, Bulgaria

  • Novartis Investigative Site

    Plovdiv, Bulgaria

  • Novartis Investigative Site

    Sofia, Bulgaria

  • Novartis Investigative Site

    Vancouver, British Columbia, Canada

  • Novartis Investigative Site

    Sydney, Nova Scotia, Canada

Showing 40 of 146 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.